X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs FULFORD INDIA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA FULFORD INDIA CIPLA/
FULFORD INDIA
 
P/E (TTM) x 45.6 398.8 11.4% View Chart
P/BV x 4.0 6.2 64.0% View Chart
Dividend Yield % 0.3 0.1 381.5%  

Financials

 CIPLA   FULFORD INDIA
EQUITY SHARE DATA
    CIPLA
Mar-17
FULFORD INDIA
Mar-14
CIPLA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs622942 66.0%   
Low Rs458450 101.8%   
Sales per share (Unadj.) Rs181.9691.4 26.3%  
Earnings per share (Unadj.) Rs12.911.5 112.3%  
Cash flow per share (Unadj.) Rs29.315.4 190.9%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.3 128.9%  
Book value per share (Unadj.) Rs155.7380.0 41.0%  
Shares outstanding (eoy) m804.513.90 20,628.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.0 295.0%   
Avg P/E ratio x42.060.7 69.1%  
P/CF ratio (eoy) x18.445.3 40.7%  
Price / Book Value ratio x3.51.8 189.4%  
Dividend payout %15.517.4 89.1%   
Avg Mkt Cap Rs m434,5162,714 16,007.8%   
No. of employees `00023.00.4 5,189.9%   
Total wages/salary Rs m26,338505 5,215.5%   
Avg. sales/employee Rs Th6,349.16,073.0 104.5%   
Avg. wages/employee Rs Th1,143.01,137.4 100.5%   
Avg. net profit/employee Rs Th449.3100.7 446.3%   
INCOME DATA
Net Sales Rs m146,3022,696 5,425.8%  
Other income Rs m2,287125 1,823.7%   
Total revenues Rs m148,5892,822 5,265.8%   
Gross profit Rs m24,758-46 -53,357.5%  
Depreciation Rs m13,22915 87,034.9%   
Interest Rs m1,59410 16,776.8%   
Profit before tax Rs m12,22254 22,507.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,79810 18,725.0%   
Profit after tax Rs m10,35445 23,163.8%  
Gross profit margin %16.9-1.7 -983.4%  
Effective tax rate %14.717.7 83.2%   
Net profit margin %7.11.7 426.9%  
BALANCE SHEET DATA
Current assets Rs m87,3701,738 5,026.2%   
Current liabilities Rs m33,081545 6,073.2%   
Net working cap to sales %37.144.3 83.8%  
Current ratio x2.63.2 82.8%  
Inventory Days Days8748 179.4%  
Debtors Days Days624 1,447.4%  
Net fixed assets Rs m111,56712 937,539.5%   
Share capital Rs m1,60939 4,125.6%   
"Free" reserves Rs m123,6451,443 8,568.6%   
Net worth Rs m125,2541,482 8,451.7%   
Long term debt Rs m36,4540-   
Total assets Rs m209,5322,077 10,089.7%  
Interest coverage x8.76.7 129.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.3 53.8%   
Return on assets %5.72.6 218.5%  
Return on equity %8.33.0 274.1%  
Return on capital %8.54.3 197.5%  
Exports to sales %34.20-   
Imports to sales %8.324.5 34.1%   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203659 1,850.9%   
Fx inflow Rs m51,06617 296,897.1%   
Fx outflow Rs m17,678673 2,626.1%   
Net fx Rs m33,388-656 -5,090.0%   
CASH FLOW
From Operations Rs m23,82490 26,470.8%  
From Investments Rs m-13,127105 -12,549.2%  
From Financial Activity Rs m-13,239-14 93,890.1%  
Net Cashflow Rs m-2,478181 -1,372.9%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 3.8 321.1%  
FIIs % 23.7 0.1 23,700.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.2 123.6%  
Shareholders   161,166 4,783 3,369.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 24, 2018 01:59 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS